Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) Sellers Increased Their Shorts By 9.18% As Of Jun 29, 2018

June 29, 2018 - By Marcos Kline

It was showed an increase on Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL)’s short interest with 9.18%. FINRA published short interest of ZEAL’s total 254,500 shares. That’s 9.18% up from 233,100 shares. With Average volume 6,100, ZEAL’s previous position will take 42 days to restore. 1.1% is Zealand Pharma A/S – American Depositary Shares float short.

ZEAL is reaching $13 during the last trading session, after increased 0.54%.Zealand Pharma A/S has volume of 3,000 shares. Since June 29, 2017 ZEAL has 0.00% and is . The stock underperformed the S&P500 by 12.57%.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics medicines in Denmark.The firm is valued at $424.62 million. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases.Currently it has negative earnings. The firm markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Another two news for Zealand Pharma A/S (NASDAQ:ZEAL) were briefly brought out by: Streetinsider.com on June 08, 2018 with title “Zealand Pharma (ZEAL) Phase 3 Trial of Dasiglucagon Met Primary and Secondary Objectives”. The other Seekingalpha.com‘s article was titled “Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved” and brought out on June 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: